Is LUV Stock a Buy, Sell or Hold?
Southwest Airlines (NYSE:LUV) is one of America’s major air transportation…
Sell
31
SAGE Quote, Financials, Valuation and Earnings
Last price:
$7.47
Seasonality move
:
6.64%
Day range:
$7.70 - $7.97
52-week range:
$4.62 - $17.51
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
11.45x
P/B ratio:
1.03x
Volume:
823.4K
Avg. volume:
1.3M
1-year change:
-54.96%
Market cap:
$477.7M
Revenue:
$41.2M
EPS (TTM):
-$6.59
Analysts' Opinion
-
Consensus RatingSage Therapeutics has received a consensus rating of Hold. The company's average rating is a Hold based on 0 Buy ratings, 15 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $8.05, Sage Therapeutics has an estimated upside of 3.55% from its current price of $7.77.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $5.00 representing 35.65% downside risk from its current price of $7.77.
Fair Value
-
According to the consensus of 15 analysts, Sage Therapeutics has 3.55% upside to fair value with a price target of $8.05 per share.
SAGE vs. S&P 500
-
Over the past 5 trading days, Sage Therapeutics has underperformed the S&P 500 by -11.09% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
Sage Therapeutics does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Sage Therapeutics revenues have been falling on a year-over-year basis for 1 quarter in a row. In the most recent quarter Sage Therapeutics reported revenues of $12.8M.
Earnings Growth
-
Sage Therapeutics has grown year-over-year earnings for 0 quarters straight. In the most recent quarter Sage Therapeutics reported earnings per share of -$1.56.
Enterprise value:
-26.7M
EV / Invested capital:
--
Price / LTM sales:
11.45x
EV / EBIT:
--
EV / Revenue:
-0.65x
PEG ratio (5yr expected):
--
EV / Free cash flow:
0.10x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
$31.8M
Return On Assets:
-56.97%
Net Income Margin (TTM):
-971.48%
Return On Equity:
-63.59%
Return On Invested Capital:
-63.59%
Operating Margin:
-626.87%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2023-12-31 | 2024-12-31 | |
| Income Statement | ||||||
| Revenue | $7.7M | $86.5M | $41.2M | $78M | $12.8M | |
| Gross Profit | $6.9M | $84.3M | $31.8M | $77.2M | $11.3M | |
| Operating Income | -$547M | -$546.5M | -$410.5M | -$42.3M | -$80.3M | |
| EBITDA | -$545.9M | -$545.1M | -$409.5M | -$41.9M | -$80.2M | |
| Diluted EPS | -$8.98 | -$9.05 | -$6.59 | -$0.54 | -$1.56 | |
| Period Ending | 2020-12-31 | 2021-12-31 | 2022-12-31 | 2023-12-31 | 2024-12-31 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $2.1B | $1.8B | $1.3B | $869.4M | $531.3M | |
| Total Assets | $2.2B | $1.8B | $1.4B | $882.3M | $547.2M | |
| Current Liabilities | $67.2M | $85.2M | $99.3M | $82.7M | $71.6M | |
| Total Liabilities | $86.9M | $96.3M | $103.9M | $82.7M | $82.1M | |
| Total Equity | $2.1B | $1.7B | $1.3B | $799.5M | $465.1M | |
| Total Debt | -- | -- | -- | -- | -- | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2023-12-31 | 2024-12-31 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$460M | -$540.6M | -$267.2M | -$119.5M | -$66.6M | |
| Cash From Investing | $325.4M | $442.9M | $266.7M | $42.1M | $46.6M | |
| Cash From Financing | $3.1M | $6M | $10.7M | -$262K | -$2K | |
| Free Cash Flow | -$461M | -$541.1M | -$267.2M | -$119.4M | -$66.6M | |
SAGE
Sector
Market Cap
$477.7M
$35.9M
Price % of 52-Week High
44.39%
43.21%
Dividend Yield
0%
0%
Shareholder Yield
--
-0.91%
1-Year Price Total Return
-54.96%
-43.29%
Beta (5-Year)
0.477
0.746
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Sell
Level
$8.23
200-day SMA
Sell
Level
$7.77
Bollinger Bands (100)
Buy
Level
5.57 - 7.65
Chaikin Money Flow
Sell
Level
-36.3M
20-day SMA
Sell
Level
$7.96
Relative Strength Index (RSI14)
Sell
Level
48.49
ADX Line
Buy
Level
25.7
Williams %R
Buy
Level
-90.4348
50-day SMA
Buy
Level
$7.51
MACD (12, 26)
Buy
Level
0.21
25-day Aroon Oscillator
Buy
Level
52
On Balance Volume
Sell
Level
-37.4M
Financial Scores
Sell
Altman Z-Score
(Annual)
Level (-6.5576)
Sell
CA Score
(Annual)
Level (-1.2663)
--
Beneish M-Score
(Annual)
Level (--)
Sell
Momentum Score
Level (1)
Sell
Ohlson Score
Level (8.0259)
Sell
Piotroski F Score
(Annual)
Level (2)
Sell
Quality Ratio Score
Level (1)
Buy
Fundamental Score
Level (4)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Sage Therapeutics Inc is a clinical-stage biopharmaceutical company focused on brain health medicines. The company is targeting diseases and disorders of the brain with three key focus areas: depression, neurology and neuropsychiatry; also targeting two critical central nervous system, or CNS, receptor systems, GABA and NMDA. Its products ZURZUVAE is a medicine for the treatment of postpartum depression, or PPD, in adults, and ZULRESSO is a CIV injection for the treatment of postpartum depression in individuals 15 years old and older. It also has other drugs in its pipeline such as SAGE-324, Dalzanemdor (SAGE-718) among others.
Stock Forecast FAQ
In the current month, SAGE has received 0 Buy ratings 15 Hold ratings, and 0 Sell ratings. The SAGE average analyst price target in the past 3 months is $8.05.
-
Where Will Sage Therapeutics Stock Be In 1 Year?
According to analysts, the consensus estimate is that Sage Therapeutics share price will rise to $8.05 per share over the next 12 months.
-
What Do Analysts Say About Sage Therapeutics?
Analysts are divided on their view about Sage Therapeutics share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Sage Therapeutics is a Sell and believe this share price will drop from its current level to $5.00.
-
What Is Sage Therapeutics's Price Target?
The price target for Sage Therapeutics over the next 1-year time period is forecast to be $8.05 according to 15 Wall Street analysts, 0 of them rate the stock a Buy, 0 rate the stock a Sell, and 15 analysts rate the stock a Hold.
-
Is SAGE A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Sage Therapeutics is a Hold. 15 of 15 analysts rate the stock a Hold at this time.
-
How Can I Buy Shares Of SAGE?
You can purchase shares of Sage Therapeutics via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, tastytrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Sage Therapeutics shares.
-
What Is The Sage Therapeutics Share Price Today?
Sage Therapeutics was last trading at $7.47 per share. This represents the most recent stock quote for Sage Therapeutics. Yesterday, Sage Therapeutics closed at $7.77 per share.
-
How To Buy Sage Therapeutics Stock Online?
In order to purchase Sage Therapeutics stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Should I Buy Alcoa Stock?
Alcoa (AA) finds itself in an interesting position in early…
Where Will Nu Holdings Stock Be in 2030?
Despite fast growth, high profitability and an extraordinary runway ahead,…
Stock Ideas
Sell
46
Is AAPL Stock a Buy?
Market Cap: $3.1T
P/E Ratio: 34x
Sell
47
Is MSFT Stock a Buy?
Market Cap: $2.8T
P/E Ratio: 32x
Sell
44
Is NVDA Stock a Buy?
Market Cap: $2.7T
P/E Ratio: 38x
Alerts
Sell
43
MNPR alert for Apr 3
Monopar Therapeutics [MNPR] is down 7.22% over the past day.
Buy
75
BKTI alert for Apr 3
BK Technologies [BKTI] is down 10.01% over the past day.
Sell
34
SWTX alert for Apr 3
SpringWorks Therapeutics [SWTX] is down 6.02% over the past day.
